Hester Biosciences Limited

HESTERBIO

INE782E01017

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:13:56 2024-05-02 am EDT			5-day change	1st Jan Change
1,698 ^INR	+3.14%		+2.76%	+16.38%

Feb. 29	Hester Biosciences Names COO	MT
Feb. 29	Hester Biosciences Limited Announces Executive Changes	CI

Hester Biosciences Limited Recommends Dividend for the Financial Year 2021-22

May 20, 2022 at 03:20 am EDT

Hester Biosciences Limited, at the board meeting held on May 20, 2022 recommended dividend of 100% that is INR 10 per equity share of INR 10 each for the financial year 2021-22, subject to approval of members in the upcoming Annual General Meeting.

Latest news about Hester Biosciences Limited

Hester Biosciences Names COO	Feb. 29	MT
Hester Biosciences Limited Announces Executive Changes	Feb. 29	CI
Hester Biosciences Sees Sharp Decline in Fiscal Q3 Consolidated Profit	Feb. 02	MT
Transcript : Hester Biosciences Limited, Q3 2024 Earnings Call, Feb 02, 2024	Feb. 02
Hester Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 02	CI
CARE Ratings Keeps BBB+ Rating on Hester Biosciences' Bank Financing; Outlook Stable	Jan. 03	MT
Transcript : Hester Biosciences Limited, Q2 2024 Earnings Call, Nov 07, 2023	Nov. 07
Hester Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 07	CI
Hester Biosciences Limited Recommends Dividend for the Financial Year 2022-23, Dividend Payment Date on or After Monday, 25 September 2023	23-08-23	CI
Transcript : Hester Biosciences Limited, Q1 2024 Earnings Call, Aug 08, 2023	23-08-08
Hester Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-08	CI
Hester Biosciences Limited Announces Board Appointments	23-06-27	CI
Transcript : Hester Biosciences Limited, Q4 2023 Earnings Call, May 17, 2023	23-05-17
Hester Biosciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-17	CI
Hester Biosciences Limited Recommends Dividend for the Financial Year 2022-23	23-05-17	CI
Hester Biosciences Limited Announces Resignation of Directors	23-03-27	CI
Hester Biosciences Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	23-01-31	CI
Transcript : Hester Biosciences Limited, Q3 2023 Earnings Call, Jan 31, 2023	23-01-31
Hester Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-01-31	CI
Hester Biosciences Limited completed the acquisition of 22.5% stake in Thrishool Exim Limited.	22-12-30	CI
Hester Biosciences Acquires Indigenous Technology for Avian Influenza Vaccine	22-12-28	MT
Hester Signs Agreement Towards Receiving Indigenously Developed Technology from Indian Council of Agricultural Research	22-12-28	CI
Transcript : Hester Biosciences Limited, Q2 2023 Earnings Call, Nov 04, 2022	22-11-04
Hester Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-04	CI
Transcript : Hester Biosciences Limited, Q1 2023 Earnings Call, Aug 10, 2022	22-08-10

Chart Hester Biosciences Limited

Duration

Period

More charts

Company Profile

Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.

Sector

Pharmaceuticals

Calendar

2024-05-14 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
HESTER BIOSCIENCES LIMITED	+16.38%	168M
ELANCO ANIMAL HEALTH INCORPORATED	-9.97%	6.48B
BLUESTAR ADISSEO COMPANY	+24.75%	3.7B
VIRBAC	-3.20%	3.1B
VIMIAN GROUP AB	+2.53%	1.44B
JINYU BIO-TECHNOLOGY CO., LTD.	-15.13%	1.37B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-25.63%	1.24B
VETOQUINOL SA	-6.64%	1.19B
WUHAN KEQIAN BIOLOGY CO.,LTD	-10.84%	1.17B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-.--%	1.05B

Veterinary Drugs